20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -66.29% | -58.43% | -2.83% | -5.00% | 38.78% |
| Total Depreciation and Amortization | -10.95% | -4.74% | -5.38% | -5.11% | -27.91% |
| Total Amortization of Deferred Charges | 145.56% | 469.19% | -- | -- | -- |
| Total Other Non-Cash Items | 74.97% | 211.42% | 0.00% | 0.00% | -80.88% |
| Change in Net Operating Assets | -124.61% | 2.26% | 93.50% | 13.20% | 968.38% |
| Cash from Operations | -151.91% | -32.67% | 24.55% | -4.69% | 8.98% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -39.31% | -18.69% | 1,347.43% | -50.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -49.97% | 74.82% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,090.79% | -- | -- | -- | -- |
| Cash from Financing | 1,042.41% | -22.46% | 286.13% | -49.98% | 138.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,785.53% | -198.35% | 131.82% | -68.14% | 47.00% |